WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single ...

Tremelimumab, a cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody, did not significantly prolong overall survival in patients with previously treated malignant mesothelioma when ...

In Study 22, the tremelimumab/Imfinzi regimen achieved a median overall survival (OS) of 18.7 months, a finding which AZ’s head of oncology R&D José Baselga said could “change the treatment ...

If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Tremelimumab given at two dosing regimens afforded durable tumor responses in patients with ...

AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results. The drugmaker said ...

The patients had all been treated with durvalumab/tremelimumab at Iwate Medical University in Japan between 2023 and 2024. The median age was 75.9 years and 86.4% were male. During the observation ...

The approval was based on data from a phase 3 POSEIDON study. The Food and Drug Administration (FDA) has approved Imjudo (tremelimumab-actl) in combination with Imfinzi (durvalumab) and platinum ...

It’s been a long road, but Astrazeneca plc’s anti-CTLA4 antibody, tremelimumab, finally earned its first U.S. FDA nod, cleared for use in combination with anti-PD-L1 drug Imfinzi (durvalumab) to treat ...

Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable ...